The influence of gonadal hormones on skeletal health in men

C. Meier; M. E. Kraenzlin

doi:10.1055/s-0038-1630135

Osteologie, Table of Contents

Osteologie 2013; 22(04): 253-259
DOI: 10.1055/s-0038-1630135

Osteoporosis in men

Schattauer GmbH

The influence of gonadal hormones on skeletal health in men

Sexualhormone und ihre Bedeutung in der Entstehung der männlichen Osteoporose

C. Meier

¹Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz

,

M. E. Kraenzlin

¹Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz

› Author Affiliations

Abstract

Summary

Osteoporosis in men has only recently begun to receive more attention despite it being estimated that about one third of all osteoporotic fractures occur in men and that the residual lifetime fracture risk in a man aged 60 years may be as high as 30 %. Accrual of bone mass and age-related bone loss in aging healthy men are multifactorial processes involving hormonal, environmental, and genetic factors. This review will summarise the effects of gonadal steroids on bone turnover and bone mass in both, men with over hypogonadism and healthy elderly men with age-related androgen deficiency.

Zusammenfassung

Die Osteoporose bei Männern wird nach wie vor unterschätzt, obwohl etwa ein Drittel aller osteoporotischen Frakturen bei Männern auftreten und das Risiko, bei normaler Lebenserwartung eine Fraktur zu erleiden, bei Männern bis zu 30 % betragen kann. Der Mineralgehaltsaufbau in der Adoleszenz und der nach Erreichen der maximalen Knochenmasse beginnende Knochenmasseverlust im Alter sind multifaktoriell bedingt. Dabei spielen hormonelle und genetische Faktoren sowie Komorbiditäten eine entscheidende Rolle. In dieser Übersichtsarbeit werden die Wirkung gonadaler Hormone auf den Knochenstoffwechsel und die Knochenmasse beim Mann zusammengefasst und am Beispiel des männlichen Hypogonadismus bzw. skelettaler Veränderungen bei altersbedingter Androgendefizienz illustriert.

Keywords

Osteoporosis in men - testosterone - estradiol

Schlüsselwörter

Osteoporose bei Männern - Testosteron - Estradiol

Full Text

References

References
1 Handelsman DJ. Androgen action and pharmacologic uses. In: DeGroot L. ed Endocrinology. Philadelphia: W. B. Saunders; 2001: 2232-2242.
2 de Ronde W, Pols HA, van Leeuwen JP, de Jong FH. The importance of oestrogens in males. Clin Endocrinol (Oxf) 2003; 58 (5) 529-542.
3 Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44 (7) 671-684.
4 Liu PY, Swerdloff RS, Veldhuis J. The rationale, efficacy and safety of androgen therapy in older men: Future research and current practice recommendations. J Clin Endocrinol Metab 2004; 89 (10) 4789-4796.
5 Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005; 152 (3) 471-478.
6 Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24 (3) 313-340.
7 Feldman HA, Longcope C, Derby CA. et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87 (2) 589-598.
8 Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5 (2) 98-102.
9 Khosla S, Melton 3rd LJ, Atkinson EJ. et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83 (7) 2266-2274.
10 Seeman E. Invited Review: Pathogenesis of osteoporosis. J Appl Physiol 2003; 95 (5) 2142-2151.
11 Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359 (9320) 1841-1850.
12 Khosla S, Melton 3rd LJ, Riggs BL. Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87 (4) 1443-1450.
13 Riggs BL, Khosla S, Melton 3rd LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23 (3) 279-302.
14 Smith EP, Boyd J, Frank GR. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331 (16) 1056-1061.
15 Smith EP, Specker B, Bachrach BE. et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab. 2008 93. (8) 3088-3096. PubMed PMID: 18505767.
16 Meier C, Seibel MJ, Handelsman DJ. Testicular dysfunction and bone. In: Orwoll E, Bilezikian J, Vanderschueren D. eds Osteoporosis in men. San Diego: Academic Press; 2010: 179-184.
17 Saad F, Adachi JD, Brown JP. et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26 (33) 5465-5476.
18 Luisetto G, Mastrogiacomo I, Bonanni G. et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporos Int 1995; 5 (6) 455-461.
19 Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003; 88 (2) 622-626.
20 Groth KA, Skakkebaek A, Host C. et al. Clinical review: Klinefelter syndrome – a clinical update. J Clin Endocrinol Metab 2013; 98 (1) 20-30.
21 Aminorroaya A, Kelleher S, Conway AJ. et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152 (6) 881-886.
22 Behre HM, Kliesch S, Leifke E. et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82 (8) 2386-2390.
23 Vanderschueren D, Vandenput L, Boonen S. et al. Androgens and bone. Endocr Rev 2004; 25 (3) 389-425.
24 Wang C, Swedloff RS, Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85 (8) 2839-2853.
25 Wang C, Cunningham G, Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89 (5) 2085-2098.
26 Wang C, Swerdloff R, Kipnes M. et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89 (8) 3821-3829.
27 Szulc P, Munoz F, Claustrat B. et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86 (1) 192-199.
28 Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86 (8) 3555-3561.
29 Meier C, Liu PY, Handelsman DJ, Seibel MJ. Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf) 2005; 63 (6) 603-616.
30 Gennari L, Merlotti D, Martini G. et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88 (11) 5327-5333.
31 Slemenda CW, Longcope C, Zhou L. et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100 (7) 1755-1759.
32 Greendale GA, Edelstein S, Barrett Connor. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12 (11) 1833-1843.
33 Kenny AM, Prestwood KM, Marcello KM, Raisz LG. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 2000; 55 (9) M492-M497.
34 Mellstrom D, Johnell O, Ljunggren O. et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21 (4) 529-535.
35 Goderie-Plomp HW, van der Klift M, de Ronde W. et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 2004; 89 (7) 3261-3269.
36 Amin S, Zhang Y, Felson DT. et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119 (5) 426-433.
37 Bjornerem A, Emaus N, Berntsen GK. et al. Circulating sex steroids, sex hormone-binding globulin, and longitudinal changes in forearm bone mineral density in postmenopausal women and men: the Tromso study. Calcif Tissue Int 2007; 81 (2) 65-72.
38 Kuchuk NO, van Schoor NM, Pluijm SM. et al. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf) 2007; 67 (2) 295-303.
39 Mellstrom D, Vandenput L, Mallmin H. et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23 (10) 1552-1560.
40 Meier C, Kraenzlin ME, Bodmer M. et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168 (8) 820-825.
41 Spitzer M, Huang G, Basaria S. et al. Risks and benefits of testosterone therapy in older men. Nature reviews Endocrinology 2013; 9 (7) 414-424.
42 Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75 (4) 1092-1098.
43 Snyder PJ, Peachey H, Hannoush P. et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84 (6) 1966-1972.
44 Amory JK, Watts NB, Easley KA. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89 (2) 503-510.
45 Kenny AM, Prestwood KM, Gruman CA. et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56 (5) M266-M272.
46 Tracz MJ, Sideras K, Bolona ER. et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91 (6) 2011-2016.
47 Wang C, Nieschlag E, Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159 (5) 507-514.
48 Falahati-Nini A, Riggs BL, Atkinson EJ. et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106 (12) 1553-1560.
49 Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16 (11) 2118-2125.
50 Meier C, Liu PY, Ly LP. et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004; 89 (6) 3033-3041.
51 Leder BZ, LeBlanc KM, Schoenfeld DA. et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88 (1) 204-210.
52 Pederson L, Kremer M, Judd J. et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999; 96 (2) 505-510.
53 Meier C, Nguyen TV, Handelsman DJ. et al. Endogenous sex hormones and incident fracture risk in older men. Arch Intern Med 2008; 168 (1) 47-54.